Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial

Journal of Dermatological Science

Volumn 59, Issue 1, 2010, Pages 40-49

  Torii, Hideshi ^a   Nakagawa, Hidemi ^b  

^a Social Insurance Central General Hospital   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ACR; DLQI; PASI; PGA

Indexed keywords

CYCLOSPORIN; ETRETINATE; INFLIXIMAB; PLACEBO; ANTIBODY; DERMATOLOGICAL AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ACNE; ADULT; ARTHRALGIA; ARTICLE; BACKACHE; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENTAL CARIES; DERMATOLOGY LIFE QUALITY INDEX; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; FEMALE; GASTROENTERITIS; HERPES ZOSTER; HUMAN; JAPANESE; LIVER FUNCTION TEST; LUPUS LIKE SYNDROME; MALE; MONOTHERAPY; MULTICENTER STUDY; NAIL PSORIASIS SEVERITY INDEX; PAIN ASSESSMENT; PATIENT ATTITUDE; PATIENT SATISFACTION; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUVA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; TINEA PEDIS; TONGUE HYPESTHESIA; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; URTICARIA; AGED; ARTHRITIS, PSORIATIC; BLOOD; IMMUNOLOGY; MIDDLE AGED; PAIN; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; ARTHRALGIA; ARTHRITIS, PSORIATIC; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PAIN; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77953616679     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2010.04.014     Document Type: Article

References (20)

1. Bonifati C., Carducci M., Cordiali Fei P., Trento E., Sacerdoti G., Fazio M., et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients-relationships with disease severity. Clin Exp Dermatol 1994, 19:383-387.
2. Mussi A., Bonifati C., Carducci M., D'Agosto G., Pimpinelli F., D'Urso D., et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997, 11:115-118.
3. Partsch G., Steiner G., Leeb B.F., Dunky A., Broll H., Smolen J.S. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997, 24:518-523.
4. Ritchlin C., Haas-Smith S.A., Hicks D., Cappuccio J., Osterland C.K., Looney R.J. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998, 25:1544-1552.
5. Reich K., Nestle F.O., Papp K., Ortonne J.P., Evans R., Guzzo C., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005, 366:1367-1374.
6. Menter A., Feldman S.R., Weinstein G.D., Papp K., Evans R., Guzzo C., et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007, 56(31):e1-e15.
7. Antoni C.E., Kavanaugh A., van der Heijde D., Beutler A., Keenan G., Zhou Bei, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the infliximab multinational psoriatic arthritis controlled trial. IMPACT 2008, 35:869-876.
8. Antoni C., Krueger G.G., de Vlam K., Birbara C., Beutler A., Guzzo C., et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005, 64:1150-1157.
9. Takeuchi T., Tatsuki Y., Nogami Y., Ishiguro N., Tanaka Y., Yamanaka H., et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67:189-194.
10. Chandran V., Raychaudhuri S.P. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010, 34:314-321.
11. Tsunemi Y., Nishibu A., Saeki H., Oyama N., Nakamura K., Kishimoto M., et al. Lack of association between the promoter polymorphisms at positions -308 and -238 of the tumor necrosis factor alpha gene and psoriasis vulgaris in Japanese patients. Dermatology 2003, 207:371-374.
12. Fredriksson T., Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978, 157:238-244.
13. Rich P., Scher R.K. Nail Psoriasis Severity Index: a useful tool for evalution of nail psoriasis. J Am Acad Dermatol 2003, 49:206-212.
14. Pincus T., Summey J.A., Soraci S.A., Wallston K.A., Hummon N.P. Assessment of patient satisfaction in activities of daily living using a modified Standford Health Assessment Questionnaire. Arthritis Rheum 1983, 26:1346-1353.
15. Felson D.T., Anderson J.J., Boers M., Bombardier C., Furst D., Goldsmith C., et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38:727-735.
16. Khilji F.A., Gonzales M., Finlay A.Y. Clinical meaning of change in dermatology life quality index scores. Br J Dermatol 2002, 147(Suppl. 62):50.
17. Bedini C., Nasorri F., Girolomoni G., Pità O., Cavani A. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function. Br J Dermatol 2007, 157:249-258.
18. Gottlieb A.B., Chamian F., Masud S., Cardinale I., Abello M.V., Lowes M.A., et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005, 175(4):2721-2729.
19. Zaba L.C., Cardinale I., Gilleaudeau P., Sullivan-Whalen M., Suárez-Fariñas M., Fuentes-Duculan J., et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007, 204:3183-3194.
20. Ortega C, Fernández AS, Carrillo JM, Romero P, Molina IJ, Moreno JC, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 2009; 86:435-43.